• Estradiol, GPR30, and Immunity After Shock

  2026-10-10

  The reference study connects hemorrhagic shock-induced impairment of splenic CD4+ T lymphocyte function with excessive endoplasmic reticulum stress and identifies receptor-selective evidence implicating ERα and GPR30, but not ERβ. Its pharmacological framework positions G-1 as a useful mechanistic probe for studying estrogen-linked immune signaling while leaving clinical translation and receptor-specific causality unresolved.

• Metabolomics Reveals Carbapenemase Resistance

  2026-10-09

  A 2025 study used LC-MS/MS metabolomics and supervised machine learning to distinguish carbapenemase-producing Enterobacterales from non-producing isolates through cellular metabolite signatures. Its findings identify candidate biomarkers and resistance-associated pathways, while also showing why external validation is necessary before clinical diagnostic use.

• Poly(A) Tailing as a Translational Lever

  2026-10-09

  Poly(A) tail architecture is a strategic variable in IVT mRNA development, influencing transcript persistence, ribosome engagement, and comparability across research programs. This thought-leadership analysis connects the HyperScribe™ Poly (A) Tailing Kit with findings from a mouse thrombopoietin mRNA study while defining the evidence boundaries between enabling research technology and therapeutic validation.

• Dyngo-4a in LNP-Mediated T-Cell Engineering

  2026-10-08

  Dyngo-4a is a small molecule dynamin inhibitor that can serve as a mechanistic research probe for membrane trafficking questions. The 2026 Ramamurthy et al. study shows that DOTAP/DOPE lipid nanoparticles support serial mRNA delivery to human T cells with higher expression and better viability than electroporation, but it does not test Dyngo-4a or establish a dynamin-dependent mechanism. This overview separates reported findings from interpretation and defines the evidence boundaries.

• Oteseconazole: Potency Meets DDI Evidence

  2026-10-08

  Oteseconazole (VT-1161) is more than a selective fungal CYP51 inhibitor. This evidence-led analysis connects Candida susceptibility findings with transporter-mediated drug-interaction interpretation, clarifying what the data support—and where clinical extrapolation remains limited.

• Temporal Transcriptomics for Anti-EBOV Discovery

  2026-10-07

  A preprint uses time-series transcriptomics, network analysis, causal inference, and functional validation to identify host programs associated with Ebola virus replication. Its findings position Sorafenib and Thioguanine as candidate host-directed antiviral agents while emphasizing that the results remain preliminary and require independent, condition-specific validation.

• Pazopanib Hydrochloride: Evidence in Cancer Research

  2026-10-07

  A source-grounded overview of Pazopanib Hydrochloride and GW786034 in cancer research, emphasizing anti-angiogenic rationale, interpretation of in vitro response metrics, evidence strength, translational relevance, and limitations.

• Difloxacin HCl: Research Context and Evidence

  2026-10-06

  Difloxacin HCl is a quinolone antimicrobial antibiotic studied conceptually through bacterial DNA replication inhibition, antimicrobial susceptibility testing, and reported multidrug resistance reversal. The available evidence is uneven: supplier information describes proposed uses, while the supplied peer-reviewed mitosis study provides relevant cell-biology context but does not directly test difloxacin.

• Syringin in RCC Research: Evidence and Limits

  2026-10-06

  Syringin is a plant-derived phenylpropanoid glycoside being investigated in natural product research, including renal cell carcinoma (RCC) models. A 2024 Journal of Functional Foods study reported that Syringin reduced RCC cell viability, proliferation, and migration, promoted apoptosis, and increased apparent sensitivity to sunitinib through effects associated with EGFR/PI3K/Akt signaling. These findings are promising but remain preclinical: the supplied evidence is centered on computational analyses and cell-based experiments, with no demonstrated clinical benefit, human pharmacology, or definitive proof that EGFR/PI3K/Akt is the direct causal target. Botanical provenance and compound characterization should also be treated carefully when comparing studies or commercial research materials.

• IDH2, α-KG, and HIF-1α in Colorectal Cancer

  2026-10-05

  The reference study links elevated IDH2 activity with reductive citrate-cycle metabolism, α-ketoglutarate depletion, HIF-1α stabilization, glycolytic activity, and colorectal cancer progression. Its combined genetic, pharmacological, metabolic, and in vivo evidence supports IDH2 as a metabolic regulator of the hypoxia signaling pathway, while also leaving important questions about model specificity, causal mechanisms, and clinical transferability.

• DAPT (GSI-IX) in Hepatobiliary Organoid Research

  2026-10-05

  DAPT (GSI-IX) is a pharmacological tool for studying γ-secretase-dependent biology, including Notch and amyloid precursor protein processing. The available hepatobiliary organoid study establishes a human induced pluripotent stem cell model with several liver and biliary functions, but it does not directly demonstrate that DAPT caused, improved, or is required for those outcomes.

• CD38 CAR Binder Structures and Affinity Tuning

  2026-10-04

  Cheng and colleagues combine structural biology, residue-level analysis, enzymatic testing, and CAR-T functional studies to explain how two CD38 binders engage distinct antigen surfaces. Their findings show that affinity tuning can reduce CD38 CAR-T fratricide while preserving antitumor cytotoxicity, although the evidence remains preclinical and assay-dependent.

• SLU-PP-332: Evidence on ERR Signaling and Exercise

  2026-10-03

  SLU-PP-332 is an experimental ERRα ERRβ ERRγ agonist investigated as a chemical tool for studying oxidative skeletal-muscle biology. The principal published study reported increased cellular respiration, oxidative muscle-fiber characteristics, and exercise endurance in mice, while also identifying ERRα-dependent transcriptional effects. These findings support preclinical investigation, but they do not establish human efficacy, safety, therapeutic dosing, or benefits for neuroprotection, aging, or disease treatment.

• Vorinostat Workflows for Cancer Biology Research

  2026-10-02

  Build reproducible Vorinostat experiments that separate chromatin effects, growth inhibition, and mitochondrial apoptosis. This workflow is designed for epigenetic modulation in oncology, dose-response profiling, and cutaneous T-cell lymphoma model studies.

• UHRF1, DNA 5-mC, and Osteogenesis in Osteoporosis

  2026-10-01

  This study connects UHRF1-dependent DNA 5-methylcytosine regulation with super-enhancer redistribution and TGM2-controlled autophagic flux in senile osteoporosis. Its multi-omics and functional experiments identify the UHRF1–TGM2 axis as a mechanistic explanation for impaired mesenchymal stem cell osteogenesis and as a potential target for rescuing bone loss.

7963 records 1/531 page Next 12345 下5页 Last page